Navigation path


Molecular and functional genomic approaches to novel antibacterial target discovery
EC contribution
: € 2.171.791
: 48 months
Starting date
: 01/03/2006
Funding scheme
: Marie Curie Actions-Early-Stage Training
: Genomics, medical microbiology, genetically modified organisms, infectious diseases, antibacterials, novel treatments
Contract/Grant agreement number
: MEST-CT-2005-020278
Project web-site


There is currently a European fragmentation in the research field of antibacterial drug discovery. Hence a co-operative collaborative approach is required to implement new approaches for the discovery of novel antibacterials through the establishment of a competitive early stage training programme which will deliver an increased number of appropriately trained experts with skills in the key complementary areas addressed within this proposal. The ANTIBIOTARGET project will establish an innovative research-driven training programme in state-of-the-art technologies in the fields of molecular bacterial pathogenicity, functional genomics and biological chemistry directed towards the development of novel antibacterial therapies which combat the disease-causing and natural antibiotic resistance capacity of pathogenic bacteria.


Infectious diseases account for more than 13 million deaths a year (one in two deaths in developing countries) and are the main causes of mortality and morbidity around the world. Increasing human mobility and changing social patterns as well as the increasing number of immuno-compromised individuals as a result of ageing populations, AIDs and advances in surgery and cancer chemotherapy, have all increased the spread and risk of infection. Furthermore, the WHO has stated that "no population is more vulnerable to multi-drug resistance than those admitted to hospital wards". Consequently, the spread of antibiotic resistant bacteria in hospitals means that medical procedures once previously taken for granted may have to be abandoned with enormous impacts on morbidity and mortality.

[+] Read More